19 research outputs found
Sentinel site community surveillance of mortality and nutritional status in southwestern Central African Republic, 2010.
BACKGROUND: During 2010, a community-based, sentinel site prospective surveillance system measured mortality, acute malnutrition prevalence, and the coverage of a Médecins Sans Frontières (MSF) intervention in four sous-préfectures of Lobaye prefecture in southwestern Central African Republic. We describe this surveillance system and its evaluation. METHODS: Within 24 randomly selected sentinel sites, home visitors performed a census, weekly demographic surveillance of births, deaths, and in- or out-migration, and weekly anthropometry on a sample of children. We evaluated the system through various methods including capture-recapture analysis and repeat census. RESULTS: The system included 18,081 people at baseline. Over 32 weeks, the crude death rate was 1.0 (95% confidence interval [CI]: 0.8-1.2) deaths per 10,000 person-days (35 deaths per 1,000 person-years), with higher values during the rainy season. The under-5 death rate was approximately double. The prevalence of severe acute malnutrition (SAM) was 3.0% (95% CI: 2.3-4.0), almost half featuring kwashiorkor signs. The coverage of SAM treatment was 29.1%. The system detected >90% of deaths, and >90% of death reports appeared valid. However, demographic surveillance yielded discrepancies with the census and an implausible rate of population growth, while the predictive value of SAM classification was around 60%. DISCUSSION: We found evidence of a chronic health crisis in this remote region. MSF's intervention coverage improved progressively. Mortality data appeared valid, but inaccuracies in population denominators and anthropometric measurements were noted. Similar systems could be implemented in other remote settings and acute emergencies, but with certain technical improvements
Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis.
Two new rotavirus vaccines have recently been licensed in many countries. However, their efficacy has only been shown against certain serotypes commonly circulating in Europe, North America, and Latin America, but thought to be globally important. To assess the potential impact of these vaccines in sub-Saharan Africa, where rotavirus mortality is high, knowledge of prevalent types is essential because an effective rotavirus vaccine is needed to protect against prevailing serotypes in the community. We did two systematic reviews and two meta-analyses of the most recent published data on the burden of rotavirus disease in children aged under 5 years and rotavirus serotypes circulating in countries in sub-Saharan Africa. Eligible studies were selected from PubMed/Medline, Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the African Index Medicus. Depending on the heterogeneity, DerSimonian-Laird random-effects or fixed-effects models were used for meta-analyses. Geographical variability in rotavirus burden within countries in sub-Saharan Africa is substantial, and most countries lack information on rotavirus epidemiology. We estimated that annual mortality for this region was 243.3 (95% CI 187.6-301.7) deaths per 100,000 under 5 years (ie, a total of 300,000 children die of rotavirus infection in this region each year). The most common G type detected was G1 (34.9%), followed by G2 (9.1%), and G3 (8.6%). The most common P types detected were P[8] (35.5%) and P[6] (27.5%). Accurate information should be collected from surveillance based on standardised methods in these countries to obtain comparable data on the burden of disease and the circulating strains to assess the potential impact of vaccine introduction
Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources
BACKGROUND: The volume, extent and speed of travel have dramatically increased in the past decades, providing the potential for an infectious disease to spread through the transportation network. By collecting information on the suspected place of infection, existing surveillance systems in industrialized countries may provide timely information for areas of the world without adequate surveillance currently in place. We present the results of a case study using reported cases of Shigella dysenteriae serotype 1 (Sd1) in European travellers to detect "events" of Sd1, related to either epidemic cases or endemic cases in developing countries. METHODS: We identified papers from a Medline search for reported events of Sd1 from 1940 to 2002. We requested data on shigella infections reported to the responsible surveillance entities in 17 European countries. Reports of Sd1 from the published literature were then compared with Sd1 notified cases among European travellers from 1990 to 2002. RESULTS: Prior to a large epidemic in 1999–2000, no cases of Sd1 had been identified in West Africa. However, if travellers had been used as an early warning, Sd1 could have been identified in this region as earlier as 1992. CONCLUSION: This project demonstrates that tracking diseases in European travellers could be used to detect emerging disease in developing countries. This approach should be further tested with a view to the continuous improvement of national health surveillance systems and existing European networks, and may play a significant role in aiding the international public health community to improve infectious disease control
Responding to nutritional crises in Niger: research in action in the region of Maradi
Despite developments to address childhood malnutrition and its determinants, eradicating childhood malnutrition remains evasive. From a public health perspective, malnutrition constitutes the single biggest contributor to under-five mortality. With a total population of about 17 million and 70% living on less than US$ 1 per day, Niger routinely ranks at the bottom of development indices. Household food production is linked to rain-fed agriculture, where staple crops such as millet and sorghum are harvested once per year. Each year, the decrease in food quantity and quality in the months preceding the harvest (August to October) is associated with an increase in wasting among children, known as the “hunger gap.”  Maradi, located in the south-central part of the country has some of the highest rates of malnutrition in the country. This was particularly dramatic in 2005, when millet prices reached levels inaccessible to large segments of the population. Subsequent to the crisis in 2005, two major developments occurred in response to nutritional crises: a change in the definition of malnutrition and uptake of new prevention options. This paper discusses some of the barriers and innovations with respect to these two changes via a series of studies conducted in the region
Responding to nutritional crises in Niger: research in action in the region of Maradi
Despite developments to address childhood malnutrition and its determinants, eradicating childhood malnutrition remains evasive. From a public health perspective, malnutrition constitutes the single biggest contributor to under-five mortality. With a total population of about 17 million and 70% living on less than US$ 1 per day, Niger routinely ranks at the bottom of development indices. Household food production is linked to rain-fed agriculture, where staple crops such as millet and sorghum are harvested once per year. Each year, the decrease in food quantity and quality in the months preceding the harvest (August to October) is associated with an increase in wasting among children, known as the “hunger gap.”  Maradi, located in the south-central part of the country has some of the highest rates of malnutrition in the country. This was particularly dramatic in 2005, when millet prices reached levels inaccessible to large segments of the population. Subsequent to the crisis in 2005, two major developments occurred in response to nutritional crises: a change in the definition of malnutrition and uptake of new prevention options. This paper discusses some of the barriers and innovations with respect to these two changes via a series of studies conducted in the region
Les enjeux pour l élimination de la rougeole en Afrique à travers l exemple d une flambée inattendue et de grande ampleur au Malawi en 2010
PARIS7-Xavier Bichat (751182101) / SudocSudocFranceF
Recommended from our members
Using simulation to aid trial design: Ring-vaccination trials
Background: The 2014–6 West African Ebola epidemic highlights the need for rigorous, rapid clinical trial methods for vaccines. A challenge for trial design is making sample size calculations based on incidence within the trial, total vaccine effect, and intracluster correlation, when these parameters are uncertain in the presence of indirect effects of vaccination. Methods and findings We present a stochastic, compartmental model for a ring vaccination trial. After identification of an index case, a ring of contacts is recruited and either vaccinated immediately or after 21 days. The primary outcome of the trial is total vaccine effect, counting cases only from a pre-specified window in which the immediate arm is assumed to be fully protected and the delayed arm is not protected. Simulation results are used to calculate necessary sample size and estimated vaccine effect. Under baseline assumptions about vaccine properties, monthly incidence in unvaccinated rings and trial design, a standard sample-size calculation neglecting dynamic effects estimated that 7,100 participants would be needed to achieve 80% power to detect a difference in attack rate between arms, while incorporating dynamic considerations in the model increased the estimate to 8,900. This approach replaces assumptions about parameters at the ring level with assumptions about disease dynamics and vaccine characteristics at the individual level, so within this framework we were able to describe the sensitivity of the trial power and estimated effect to various parameters. We found that both of these quantities are sensitive to properties of the vaccine, to setting-specific parameters over which investigators have little control, and to parameters that are determined by the study design. Conclusions: Incorporating simulation into the trial design process can improve robustness of sample size calculations. For this specific trial design, vaccine effectiveness depends on properties of the ring vaccination design and on the measurement window, as well as the epidemiologic setting